The KEYNOTE-181 trial compared pembrolizumab to chemotherapy in previously treated esophageal cancer and demonstrated a significant overall survival benefit in patients with PD-L1 CPS ≥ 10 (9.3 vs. 6.7 months; HR 0.69; p = 0.0074) [78]. Here, CD274 is linked to esophageal cancer.